



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

SBERESFORD@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3168


TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

December 11, 2003

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 11, 2003  
Date

  
Sharon A. Beresford

**MS DD**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/656,897 entitled "RAPID ASSAY FOR NEUROTRANSMITTER TRANSPORTERS" – Joel W. Schwartz et al.*  
*Our reference: VBLT:014US*  
*Client reference: VU0187*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A4 and C1-C75.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/VBLT:014US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials

Respectfully submitted,



Sharon Beresford  
Agent for Applicant  
Reg. No. 52,615

SAB/kmv  
Encl.: as noted

25364677.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Joel W. Schwartz *et al.*

Serial No.: 10/656,897

Filed: September 5, 2003

For: RAPID ASSAY FOR  
NEUROTRANSMITTER  
TRANSPORTERS

Group Art Unit: 1645


Examiner: Unknown

Atty. Dkt. No.: VBLT:014US

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 11, 2003  
Date

  
Sharon A. Beresford

**INFORMATION DISCLOSURE STATEMENT**

**MS DD**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/VBLT:014US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Sharon A. Beresford  
Reg. No. 52,615  
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: December 11, 2003

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

Applicant

Joel W. Schwartz *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,312,734	5/17/94	Uhl <i>et al.</i>	435	69.1	9/20/91
	A2	5,418,162	5/23/95	Blakely <i>et al.</i>	435	252.3	10/14/92
	A3	5,424,185	6/13/95	Lam and Chang	435	6	9/21/90
	A4	6,127,133	10/3/00	Akong <i>et al.</i>	435	7.2	4/18/94

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Apparsundaram <i>et al.</i> , "Molecular cloning and characterization of an <i>t</i> -epinephrine transporter from sympathetic ganglia of the bullfrog, <i>rana catesbiana</i> ," <i>J. Neurosci.</i> , 17(8):2691-2702, 1997.
	C2	Aston-Jones <i>et al.</i> , "Role of locus coeruleus in attention and behavioral flexibility," <i>Biol. Psychiatry</i> , 46:1309-1320, 1999.
	C3	Axelrod and Kopin, "The uptake, storage, release and metabolism of noradrenaline in sympathetic nerves," <i>Prog. Brain Res.</i> , 31:21-32, 1969.
	C4	Bannon, "The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders," <i>Eur. Neuropsychopharmacol.</i> , 11(6):449-455, 2001.
	C5	Barker and Blakely, "Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter," <i>Mol. Pharmacol.</i> , 50(4):957-965, 1996.
	C6	Barnes, "Breaking the cycle of addiction," <i>Science</i> , 241:1029-1030, 1988.

25345231.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

Applicant

Joel W. Schwartz *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Beiderman and Spencer, "Attention-deficit/hyperactivity disorder(ADHD) as a noradrenergic disorder," <i>Biol. Psychiatry</i> , 46:1234-1242, 1999.
	C8	Blakely and Apparsundaram, "Structural diversity in the catecholamine transporter gene family: molecular cloning and characterization of an L-epinephrine transporter from bullfrog sympathetic ganglia," <i>Adv. Pharmacol.</i> , 42:206-210, 1998.
	C9	Blakely <i>et al.</i> , "Cloning and expression of a functional serotonin transporter from rat brain," <i>Nature</i> , 354:66-70, 1991.
	C10	Blundell, "Serotonin manipulations and the structure of feeding behaviour," <i>Appetite</i> , 7(1):39-56, 1986.
	C11	Bönisch and Harder, "Binding of 3H-desipramine to the neuronal noradrenaline carrier of rat pheochromocytoma cells (PC-12 cells)," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 334:403-411, 1986.
	C12	Bönisch, "The transport of (+)-amphetamine by the neuronal noradrenaline carrier," <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , 327:267-272, 1984.
	C13	Bruns <i>et al.</i> , "A fast activating presynaptic reuptake current during serotonergic transmission in identified neurons of <i>hiduro</i> ," <i>Neuron</i> , 10:559-572, 1993.
	C14	Bruns, "Serotonin transport in cultured leech neurons," <i>Methods Enzymol.</i> , 296:593-607, 1998.
	C15	Clarkson <i>et al.</i> , "Electrophysiological effects of high cocaine concentrations on intact canine heart: evidence for modulation by both heart rate and autonomic nervous system," <i>Circulation</i> , 87:950-962, 1993.
	C16	Corey <i>et al.</i> , "A cocaine-sensitive drosophila serotonin transporter: cloning, expression, and electrophysiological characterization," <i>Proc. Natl. Acad. Sci., USA</i> , 91:1188-1192, 1994.
	C17	Coull <i>et al.</i> , "Noradrenergically mediated plasticity in a human attentional neuronal network," <i>Neuroimage</i> , 10:705-715, 1999.
	C18	DeFelice, "Visualization of single cell real-time kinetics for norepinephrine transporters using fluorescence microscopy," manuscript.
	C19	DeFelice and Galli, "Electrophysiological analysis of transporter function," <i>Adv. Pharmacol.</i> , 42:186-190, 1998.

25345231.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

Applicant

Joel W. Schwartz *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C20	DeOliveara <i>et al.</i> , "Differences in the temperature dependence of drug interaction with the noradrenaline and serotonin transporters," <i>Neuropharmacology</i> , 28(8):823-828, 1989.
	C21	Dow and Kline, "Antidepressant treatment of posttraumatic stress disorder and major depression in veterans," <i>Ann. Clin. Psychiatry</i> , 9(1):1-5, 1997.
	C22	Fleckenstein <i>et al.</i> , "Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function," <i>Eur. J. Pharmacol.</i> , 382:45-49, 1999.
	C23	Gainetdinov <i>et al.</i> , "Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter," <i>J. Neurochem.</i> , 69:1322-1325, 1997.
	C24	Galli <i>et al.</i> , "Norepinephrine transporters have channel modes of conduction," <i>PNAS</i> , 93:8671-8676, 1998.
	C25	Galli <i>et al.</i> , "Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants," <i>J. Exp. Biol.</i> , 198(10):2197-2212, 1995.
	C26	Gill <i>et al.</i> , "Effects of serotonin uptake blockade on food, water, and ethanol consumption in rats," <i>Alcoholism</i> , 11(5):444-449, 1987.
	C27	Giros <i>et al.</i> , "Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter," <i>Mol. Pharmacol.</i> , 42(3):383-390, 1992.
	C28	Giros <i>et al.</i> , "Hyperlocation and indifference to cocaine and amphetamine in mice lacking the dopamine transporter," <i>Nature</i> , 379(6566):606-612, 1996.
	C29	Glassman <i>et al.</i> , "Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman," <i>J. Nerv. Ment. Dis.</i> , 173(9):573-576, 1985.
	C30	Hadrich <i>et al.</i> , "Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents," <i>J. Med. Chem.</i> , 42:3101-3108, 1999.
	C31	Hartzell, "Distribution of muscarinic acetylcholine receptors and presynaptic nerve terminals in amphibian heart," <i>J. Cell Biol.</i> , 86:6-20, 1980.
	C32	Hatfield and McGaugh, "Norepinephrine infused into the basolateral amygdala posttraining enhances retention in a spatial water maze task," <i>Neurobiol. Learn. Mem.</i> , 71:232-239, 1999.
	C33	Herrera and Banner, "The use and effects of vital fluorescent dyes: observation of motor nerve terminals and satellite cells in living frog muscles," <i>J. Neurocytol.</i> , 19:67-83, 1990.

25345231.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Joel W. Schwartz *et al.*

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Herrera <i>et al.</i> , "Repeated, in vivo observation of frog neuromuscular junctions: remodeling involves concurrent growth and retraction," <i>J. Neurocytol.</i> , 19:85-99, 1990.
	C35	Hohage <i>et al.</i> , "Regulation of organic cation transport in IHKE-1 and LLC-PK1 cells. Fluorometric studies with 4-(4-Dimethylaminostyryl)-N-methylpyridinium," <i>J. Pharmacol. Exp. Ther.</i> , 286(1):305-310, 1998.
	C36	Iverson <i>et al.</i> , "Uptake, storage, and metabolism of norepinephrine in tissues of the developing rat," <i>J. Pharmacol. Exp. Ther.</i> , 157(3):509-516, 1967.
	C37	Jacob <i>et al.</i> , "Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance," <i>Circulation</i> , 99:1706-1712, 1999.
	C38	Jones, "Descending noradrenergic influences on pain," <i>Prog. Brain Res.</i> , 88:381-394, 1991.
	C39	Kawarai <i>et al.</i> , "Structure and organization of the gene encoding human dopamine transporter," <i>Gene</i> , Aug 11;195(1):11-8, 1997.
	C40	Kitayama <i>et al.</i> , "Functional characterization of the splicing variants of human norepinephrine transporter," <i>Neurosci. Lett.</i> , 312(2):108-112, 2001.
	C41	Koella, "Serotonin and sleep," In: <i>Neuronal Serotonin</i> , Osborne <i>et al.</i> (eds.) 153-170, 1988.
	C42	Kuhar <i>et al.</i> , "The dopamine hypothesis of the reinforcing properties of cocaine," <i>Trends Neurosci.</i> , 14(7):299-302, 1991.
	C43	Le Bars, "Serotonin and pain," In: <i>Neuronal Serotonin</i> , Osborne and Hamrin (eds.), 171-229, 1988.
	C44	Masson <i>et al.</i> , "Neurotransmitter transporters in the central nervous system," <i>Pharmacol. Rev.</i> , 51(3):439-464, 1999.
	C45	Mehrens <i>et al.</i> , "The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependant phosphorylation," <i>J. Am. Soc. Nephrol.</i> , 11:1216-1224, 2000.
	C46	Morozova <i>et al.</i> , "[4-(n-Dimethylaminostyryl)-1-methylpyridinium fluorescence in a living cell]," <i>Tsitologiya</i> , 23(8):916-923, 1981.
	C47	Naranjo <i>et al.</i> , "The serotonin uptake inhibitor citalopram attenuates ethanol intake," <i>Clin. Pharmacol. Ther.</i> , 41:266-274, 1987.

25345231.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

Applicant

Joel W. Schwartz *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C48	Nuemeister <i>et al.</i> , "Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression," <i>Arch. Gen. Psychiatry</i> , 59(7):613-620, 2002.
	C49	Pacholczyk <i>et al.</i> , "Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter," <i>Nature</i> , Mar 28; 350(6316):350-354, 1991.
	C50	Pelham, "Green light for Golgi traffic," <i>Nature</i> , 389(6646):17, 19, 1997
	C51	Pietruck and Ullrich, "Transport interactions of different organic cations during their excretion by the intact rat kidney," <i>Kidney Int.</i> , 47(6):1647-1657, 1995.
	C52	Porzgen <i>et al.</i> , "Errata," <i>Biochem. Biophys. Res. Commun.</i> , 227(2):642:643, 1996.
	C53	Prasad and Amara, "The dopamine transporter in mesencephalic cultures is refractory to physiological changes in membrane voltage," <i>J. Neurosci.</i> , 21(19):7561-7567, 2001.
	C54	Qian <i>et al.</i> , "Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression," <i>The Journal of Neuroscience</i> , 17(1):45-57, 1997.
	C55	Ramamoorthy <i>et al.</i> , "Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization," <i>Proc. Natl. Acad. Sci., USA</i> , 90:2542-2546, 1993.
	C56	Ramamoorthy <i>et al.</i> , "Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast," <i>Biochemistry</i> , 32(5):1346-1353, 1993.
	C57	Ramamoorthy, "Phosphorylation and regulation of antidepressant-sensitive serotonin transporters," <i>J. Biol. Chem.</i> , 273(4):2458-2466, 1998.
	C58	Ressler and Nemeroff, "Role of norepinephrine in the pathophysiology and treatment of mood disorders," <i>Biol. Psychiatry</i> , 46:1219-1233, 1999.
	C59	Rohlicek and Ullrich, "Simple device for continuous measurement of fluorescent anions and cations in the rat kidney in situ," <i>Ren. Physiol. Biochem.</i> , 17(2):57-61, 1994.
	C60	Rudnick and Clark, "From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters," <i>Biochim. Biophys. Acta</i> , 1144(3):249-263, 1993.
	C61	Samochowiec <i>et al.</i> , "Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationship to temperament and character inventory in healthy volunteers," <i>Neuropsychobiology</i> , 43(4):248-253, 2001.

25345231.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

Applicant

Joel W. Schwartz *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C62	Schroeter <i>et al.</i> , "Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter," <i>J. Comp. Neurol.</i> , 420(2):211-232, 2000.
	C63	Silverstone <i>et al.</i> , "Serotonergic mechanisms in human feeding: the pharmacological evidence," <i>Appetite</i> , 7 Suppl., 85-97, 1986.
	C64	Skrebtsky and Chepkova, "Hebbian synapses in cortical and hippocampal pathways," <i>Rev. Neurosci.</i> , 9:243-264, 1998.
	C65	Smith and Levi, "LLC-PK1 cells stably expressing the human norepinephrine transporter: a functional model of carrier-mediated norepinephrine release in protracted myocardial ischemia," <i>J. Pharmacol. Exp. Ther.</i> , 291(2):456-463, 1999.
	C66	Soubrié, "Serotonin and behaviour, with special regard to animal models of anxiety, depression and waiting ability," In: <i>Neuronal Serotonin</i> , Osborne and Hamon (eds.), 255-270, 1988.
	C67	Southwick <i>et al.</i> , "Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder," <i>Biol. Psychiatry</i> , 46:1192-1204, 1999.
	C68	Stachon <i>et al.</i> , "Characterisation of organic cation transport across the apical membrane of proximal tubular cells with the fluorescent dye 4-Di-1-ASP," <i>Cell Physiol. Biochem.</i> , 7:264-274, 1997.
	C69	Steffgen <i>et al.</i> , "Dynamic monitoring of organic cation transport processes by fluorescence measurements in LLC-PK1 cells," <i>Cellular Physiol. Biochem.</i> , 6:72-91, 1996.
	C70	Stöber <i>et al.</i> , "Serotonin transporter gene polymorphism and affective disorder," <i>Lancet</i> , 347(9011):1340-1341, 1996.
	C71	Tsai <i>et al.</i> , "Association for serotonin transporter gene variable number tandem repeat polymorphism and schizophrenic disorders," <i>Neuropsychobiology</i> , 45(3):131-133, 2002.
	C72	Van Woert <i>et al.</i> , "Serotonin and myoclonus," <i>Monogr. Neural. Sci.</i> , 3:71-80, 1976.
	C73	Watanabe <i>et al.</i> , "Cardiovascular effects of imipramine in intact dogs and isolated dog atria," <i>Jpn. Heart J.</i> , 22:977-985, 1981.
	C74	White, "Inhibition of synaptosomal noradrenaline uptake by veratridine, gramicidin D and valinomycin," <i>J. Neurochem.</i> , 29:193-198, 1977.

25345231.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

VBLT:014US

Serial No.

10/656,897

List of Patents and Publications for Applicant's

Applicant

J el W. Schwartz *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 5, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C75	Wu <i>et al.</i> , "Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta," <i>Biochim. Biophys. Acta.</i> , 1466:315-327, 2000.

25345231.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)